| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
908 Devices Inc.
13G/A
Amendment 6
MASS · 65443P102
|
14.1% |
8/14/2026
Event 6/30/2026
|
|||
| ARCH Venture Fund VII, L.P. | 13.9% | ||||
| ARCH Venture Partners VII, L.P. | 13.9% | ||||
| ARCH Venture Partners VII, LLC | 13.9% | ||||
| Keith Crandell | 14.1% | ||||
| Clinton Bybee | 13.9% | ||||
| Robert Nelsen | 13.9% | ||||
|
908 Devices Inc.
13G/A
Amendment 5
MASS · 65443P102
|
15.3% |
5/15/2026
Event 3/31/2026
|
|||
| ARCH Venture Fund VII, L.P. | 15.1% | ||||
| ARCH Venture Partners VII, L.P. | 15.1% | ||||
| ARCH Venture Partners VII, LLC | 15.1% | ||||
| Keith Crandell | 15.3% | ||||
| Clinton Bybee | 15.1% | ||||
| Robert Nelsen | 15.1% | ||||
|
Unity Biotechnology, Inc.
13G/A
Amendment 4
UNBX · 91381U200
|
0% |
11/14/2025
Event 9/30/2025
|
|||
| ARCH Venture Fund VII, L.P. | 0% | ||||
| ARCH Venture Fund VIII Overage, L.P. | 0% | ||||
| ARCH Venture Partners VII, L.P. | 0% | ||||
| ARCH Venture Partners VII, LLC | 0% | ||||
| ARCH Venture Partners VIII, LLC | 0% | ||||
| Keith Crandell | 0% | ||||
| Clinton Bybee | 0% | ||||
| Robert Nelsen | 0% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.